Aspafilioside B
Aspafilioside B is a steroidal saponin. Aspafilioside B is extractable from Asparagus filicinus. Aspafilioside B activates the ERK, c-Raf and p38 MAPK signaling pathways, and upregulates H-Ras and N-Ras. Aspafilioside B mediates G2/M cell cycle arrest by altering the expression of cell cycle regulatory proteins. Aspafilioside B induces Apoptosis. Aspafilioside B increases intracellular ROS levels. Aspafilioside B is applicable to research related to hepatocellular carcinoma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 131123-73-4
- Formule: C43H70O16
- Masse moléculaire:843.01
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[1]|
H-Ras |
N-Ras |
C-Raf |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
17.78 μM
|
Inhibition of cell viability against human hepatocellular carcinoma HepG2 cells incubated for 24 hrs by MTT assay.
Inhibition of cell viability against human hepatocellular carcinoma HepG2 cells incubated for 24 hrs by MTT assay.
|
25683703 |
| Huh-7 | IC50 |
13.12 μM
|
Inhibition of cell viability against human hepatocellular carcinoma Huh7 cells incubated for 24 hrs by MTT assay.
Inhibition of cell viability against human hepatocellular carcinoma Huh7 cells incubated for 24 hrs by MTT assay.
|
25683703 |
| Bel-7402 | IC50 |
16.32 μM
|
Inhibition of cell viability against human hepatocellular carcinoma BEL7402 cells incubated for 24 hrs by MTT assay.
Inhibition of cell viability against human hepatocellular carcinoma BEL7402 cells incubated for 24 hrs by MTT assay.
|
25683703 |
| SMMC-7721 | IC50 |
21.00 μM
|
Inhibition of cell viability against human hepatocellular carcinoma SMMC-7721 cells incubated for 24 hrs by MTT assay.
Inhibition of cell viability against human hepatocellular carcinoma SMMC-7721 cells incubated for 24 hrs by MTT assay.
|
25683703 |
| HepG2 | IC50 |
11.4 μM
|
Inhibition of cell viability against human hepatocellular carcinoma HepG2 cells incubated for 48 hrs by MTT assay.
Inhibition of cell viability against human hepatocellular carcinoma HepG2 cells incubated for 48 hrs by MTT assay.
|
25683703 |
| HepG2 | IC50 |
9.00 μM
|
Inhibition of cell viability against human hepatocellular carcinoma HepG2 cells incubated for 72 hrs by MTT assay.
Inhibition of cell viability against human hepatocellular carcinoma HepG2 cells incubated for 72 hrs by MTT assay.
|
25683703 |
In Vitro
Aspafilioside B (0-40 μM; 24-72 h) inhibits the viability of hepatocellular carcinoma HepG2, Huh7, BEL7402 and SMMC-7721 cells in a time- and concentration-dependent manner, with its IC50 values ranging from 9.00 μM to 21.00 μM depending on the cell line and incubation time[1].
Aspafilioside B (8-12 μM; 6-24 h) induces G2/M cell cycle arrest in human hepatocellular carcinoma HepG2 cells in vitro in a time- and concentration-dependent manner. After treatment with 12 μM for 24 h, the number of G2/M phase cells increases to 4 times the original level[1].
Aspafilioside B (8-12 μM; 6-24 h) regulates the expression of key cell cycle regulatory proteins in hepatocellular carcinoma HepG2 cells, downregulating cyclin B1, Cdc2, p-Cdc2 (Thr14/Tyr15) and Cdc25C in a time- and concentration-dependent manner, while upregulating p21WAF1/Cip1[1].
Aspafilioside B (8-12 μM; 24 h) induces apoptosis in hepatocellular carcinoma HepG2 cells in a concentration-dependent manner by activating the intrinsic apoptotic pathway and regulating key apoptosis-related proteins[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human hepatocellular carcinoma HepG2, Huh7, BEL7402, SMMC-7721 cells
-
Concentration:0-40 μM
-
Incubation Time:24 h; 24 h, 48 h, 72 h (HepG2 cells only)
-
Result:Inhibited cell viability in all four HCC cell lines in a time- and concentration-dependent manner.
Exhibited IC50 values of 17.78 μM (HepG2), 13.12 μM (Huh7), 16.32 μM (BEL7402), and 21.00 μM (SMMC-7721) after 24 h treatment.
Showed decreased IC50 values in HepG2 cells with longer incubation: 17.78 μM (24 h), 11.4 μM (48 h), and 9.00 μM (72 h).
-
Cell Line:human hepatocellular carcinoma HepG2 cells
-
Concentration:8, 10, 12 μM
-
Incubation Time:24 h; 6 h, 12 h, 24 h
-
Result:Induced G2/M phase cell cycle arrest in a time- and concentration-dependent manner.
Increased the percentage of cells in G2/M phase four-fold with 12 μM treatment for 24 h compared to controls, accompanied by a decrease in G0/G1 phase cells.
Caused evident G2/M arrest as early as 6 h after 12 μM treatment, which persisted for 24 h.
-
Cell Line:human hepatocellular carcinoma HepG2 cells
-
Concentration:8-12 μM; 12 μM
-
Incubation Time:24 h; 6 h, 12 h, 24 h
-
Result:Down-regulated protein levels of cyclin B1, Cdc2, p-Cdc2 (Thr14/Tyr15), and Cdc25C.
Up-regulated p21WAF1/Cip1 levels.
Observed these protein changes as early as 6 h after 12 μM treatment, which persisted for 24 h.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 35-40 d old, 18-22 g, subcutaneously inoculated with 1×106 HepG2 cells)[1]
-
Dosage:5 mg/kg; 10 mg/kg
-
Administration:i.p.; three times a week; 21 days
-
Result:Reduced tumor growth with an inhibitory rate of 58.29% at 10 mg/kg.
Reduced tumor growth with an inhibitory rate of 47.89% at 5 mg/kg.
Decreased resected tumor weight to 0.47 g at 10 mg/kg and 0.58 g at 5 mg/kg, compared to 1.07 g in the control group.
Increased expression of H-Ras and N-Ras in tumor tissue.
Showed no significant changes in average body weight, hematological parameters, or organ morphology compared to controls.
Chemical Information
-
CAS No. 131123-73-4
-
Masse moléculaire 843.01
-
Formule C43H70O16
-
SMILES
C[C@@]12[C@]3([H])[C@](O[C@]4(CC[C@@H](CO4)C)[C@H]3C)([H])C[C@@]1([H])[C@@]5([H])[C@]([C@@]6([C@](C[C@H](CC6)O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)CO[C@H]9[C@@H]([C@H]([C@H](CO9)O)O)O)([H])CC5)C)([H])CC2
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Aspafilioside B Related Classifications
HY-122465 Related Classifications
Powered by Bioz